Summary Infusional 5-fluorouracil (F) with cisplatin (C) and epirubicin (E), so- (Smith et al., 1995) . The schedule has also shown high activity in the treatment of advanced gastric carcinoma with a response rate of 71% (Findlay et al., 1994) .
The overall response rate (complete plus partial) was 81% (95% CI 67% -90%), with a complete response rate of 17% (95% CI 6-33%) in patients with metastatic disease and 56% (95% CI 30-80%) in patients with locally advanced disease. Median response duration and survival for metastatic disease was 8 and 14 months respectively, and two patients with locally advanced disease have relapsed. These results are very similar to those previously achieved with infusional ECF. Severe grade 3/4 toxicity was low. Infusional ECarboF is a highly active, well-tolerated, outpatient regimen effective against advanced/metastatic breast cancer and now warrants evaluation against conventional chemotherapy in high-risk early breast cancer.
Keywords: infusional chemotherapy; carboplatin; breast cancer Continuous infusional 5-fluorouracil (5-FU) for up to 6 months, with 3-weekly bolus cisplatin and epirubicin (socalled infusional ECF) has been shown to be a highly active new schedule in the treatment of locally advanced or metastatic breast cancer with an overall response rate of 84% (Jones et al., 1994) . Subsequently, the same regimen achieved an overall response rate of 98% and a complete remission rate of 66% as primary/neoadjuvant chemotherapy for large early breast cancer (Smith et al., 1995) . The schedule has also shown high activity in the treatment of advanced gastric carcinoma with a response rate of 71% (Findlay et al., 1994) .
The underlying rationale for this schedule is as follows: Phase I studies have demonstrated that 5-FU can be administered by protracted continuous infusion at a dose of 300 mg m-2 day-' without interruption for up to 60 days or up to 36 g cumulative dose (Lokich et al., 1981) ; response rates of up to 53% have been reported in patients with metastatic breast cancer extensively pretreated with chemotherapy (Huan et al., 1989) . This represents a more than 3-fold increase in response compared with conventional studies. In an overview of six phase II studies involving 182 patients with refractory breast cancer, most of whom were pretreated with bolus 5-FU, an average response rate of 29% (range 17-53%) has been reported (Hansen, 1991) . As originally suggested in the phase I study by Lokich and subsequently confirmed by phase II studies, myelosuppression, an important toxic effect occurring with bolus administration, is rarely reported with infusional 5-FU and the dose-limiting toxicities are stomatitis, diarrhoea and plantar-palmar erythema (Lokich et al., 1981; Hansen et al., 1987; Huan et al., 1989) .
Anthracyclines, including epirubicin, are still the most active drugs used as single agents in advanced breast cancer (Henderson, 1987) . Cisplatin is an active agent as first-line treatment for advanced breast cancer with an overall response rate of 50% (33 out of 66 patients) in three small studies (Kolaric and Roth, 1983; Mechl, 1988; Sledge et al., 1988) . Furthermore, clinical studies have reported a response rate of 50-53% in patients with advanced breast cancer treated wtih 5-FU administered by continuous infusion with cisplatin (Fernandez-Hidalgo et al., 1989; Bitran et al., 1990) .
There are, however, disadvantages with cisplatin. Even with modern antiemetics it is associated with significant incidence of severe nausea and vomiting and is also associated with neurotoxicity and nephrotoxicity. To prevent this last problem patients require an overnight or extended day-long admission for intravenous hydration.
Carboplatin has established advantages over cisplatin in having a reduced risk of serious emesis, nephrotoxicity or neurotoxicity (Calvert et al., 1982) . In addition, it can be given on a simple outpatient basis as a 1 h infusion. We found that in previously untreated patients with metastatic breast cancer, the carboplatin response rate was 33% (9 out of 27 patients) (O'Brien et al., 1993) , and others have reported similar findings (Carmo Pereira et al., 1990; Kolaric and Vukas, 1991; Martin et al., 1992) . For these reasons we have investigated the substitution of carboplatin to cisplatin in our original infusional ECF schedule to try to devise a simpler and more 'user friendly' infusional schedule for the treatment of breast cancer. We report here the results of our phase II study.
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eligible for the study. The criteria for locally advanced breast cancer were those reported by Haagensen and Stout (1943) . Inflammatory breast cancer was defined as a T4 lesion with diffuse brawny induration of the breast with an erysipeloid edge (Beahrs et al., 1992 
Dose modifications
Myelosuppression If the WBC count was less than 3.0 x 109 1-l and/or platelet count less than 100 x 1091 l-, 5-FU was continued but carboplatin and epirubicin were delayed for 1 week. If the blood count had recovered, treatment was then administered at full dose. If the blood count had not recovered, then treatment was delayed by 2 weeks and the doses of both epirubicin and 5-FU were reduced by 25% and the dose of carboplatin reduced from AUC5 to AUC4. If there was a longer than 2 week delay, the doses of both epirubicin and 5-FU were reduced by 50% and the dose of carboplatin reduced to AUC3.
Patients' GFR was measured by chromium-51-labelled EDTA clearance before the start of treatment and then before the fourth course. The carboplatin dose was recalculated before the fourth course on the basis of the measured GFR.
Plantar-palmar syndrome Continuous toxicity with plantar-palmar erythema is observed with infusional 5-FU. For mild to moderate plantar-palmar erythema (dryness and erythema with pain), patients continued 5-FU and were prescribed pyridoxine (50 mg orally three times per day) throughout treatment. For severe plantar-palmar erythema (severe erythema with blistering and desquamation), pyridoxine was started and 5-FU was interrupted for 1 week until healing had occurred. 5-FU was then restarted at a 25% dose reduction, and pyridoxine was continued throughout treatment.
Diarrhoea For WHO grade 1 or 2 diarrhoea, antidiarrhoeal agents were prescribed, but for persistent diarrhoea 5-FU was discontinued for 1 week and restarted at a 25% dose reduction.
Mucositis In patients with grade 3 or 4 mucositis, infusional 5-FU was stopped for 1 week and then restarted at a 25% dose reduction. Epirubicin was also subsequently given at a 25% dose reduction.
Assessment of response and toxicity Patients were examined clinically before treatment: full blood count, serum biochemistry, chest radiograph and measurement of EDTA clearance to assess renal function. Patients with metastatic disease had appropriate clinical and radiological examination according to the site of disease, and bidimensionally measurable and assessable lesions were monitored. Patients with locally advanced carcinoma were assessed clinically, as well as by mammography and ultrasound.
Patients had a clinical examination and full blood count, and a biochemistry before each cycle (28 days). Response was assessed according to standard International Union Against Cancer criteria (Hayward et al., 1977) after every two cycles and on completion of treatment. Patients were then monitored at 3 month intervals. Toxicity was assessed according to WHO criteria after each cycle of chemotherapy (WHO, 1979) . Patients who received at least two cycles of chemotherapy were assessable for response, and all patients were assessable for toxicity. The response duration was defined as the time elapsed between the start of treatment with carboplatin and the date of progressive disease or last follow-up evaluation.
Statistical considerations
This was an open-ended phase II study. The planned number of patients was 50 to determine a predicted response rate of 75% to within+ 10%.
The x2 test and Mann -Whitney test for trend were used to assess differences in toxicity between patients with metastatic and locally advanced disease. Survival analysis and duration of response were generated using the Kaplan-Meier life table method (Kaplan and Meier, 1958 Non-haematological toxicity Details of non-haematological toxicity are listed in Table V and are expressed as the worst toxicity experienced for any course. With the use of ondansetron and dexamethasone, only one patient (2%) had significant emesis. Sixteen patients (31%) had alopecia that required them to wear a wig. The main side-effect related to the 5-FU was plantar -palmar erythema, which occurred in five patients (10%); stomatitis occurred in four patients only (8%) and diarrhoea in none. Three patients developed severe somnolence (grade 3 lethargy). There were no complications related to the Hickman line insertion. Two patients (4%) developed Hickman line thrombosis, one after the first course and one after the third course. The line was removed, the patients received full anticoagulant treatment with warfarin and were continued on a 5-FU, epirubicin, cyclophosphamide chemotherapy regimen (FEC). Nine patients (17%) developed infection at the site of Hickman line insertion that required intravenous antibiotics; removal was undertaken in three cases. Prophylactic antibiotics were not prescribed, but line exit sites were carefully monitored throughout treatment and flucloxacillin prescribed at the slightest clinical suggestion of infection. In one patient the Hickman line fractured after the sixth cycle and had to be removed in a cardiac catheter laboratory. Dose reductions and delays Treatment was delayed for 1 week in 13 patients (25%), 2 weeks in four patients (8%) and more than 2 weeks in one patient (2%). Eighteen patients (35%) had a dose reduction of 5-FU: nine by 25%, four by 24-50%, and five by more than 50%. Eight patients (15%) had a dose reduction in epirubicin: five by 25%, two by 25-50% and one by more than 50%. Ten patients (19%) had a dose reduction in carboplatin: five by 25%, three by 25-50% and two by more than 50%. We have already shown that a combination of infusional 5-FU with epirubicin and cisplatin (so-called infusional ECF) is a highly active regimen in the treatment of locally advanced and metastatic breast cancer (Jones et al., 1994) . We have subsequently shown the same regimen to be very active as primary/neoadjuvant chemotherapy against large breast primaries with an overall response rate of 98% and, strikingly, a 66% complete remission rate (Smith et al., 1995) . The disadvantage of this schedule is the cisplatin. Even at the moderate dosage we use of 50 mg m-2, the treatment was associated with severe grade 3/4 nausea and vomiting in respectively 28% and 20% of patients (Jones et al., 1994; Smith et al., 1995) ; in addition, the treatment requires prolonged 8-12 h intravenous hydration and therefore necessitated either an overnight inpatient stay or a prolonged day patient admission.
Carboplatin is an attractive substitute for cisplatin in terms of reducing the incidence of severe nausea and vomiting and of neuropathy (Calvert et al., 1982) . In addition, the treatment can be given in an outpatient setting in a 1 h infusion. There are two potential concerns, however, with the substitution of carboplatin for cisplatin. Firstly, delayed myelosuppression necessitates that carboplatin is usually given on a 4 weekly rather than 3 weekly basis; epirubicin has therefore also to be given 4 weekly rather than 3 weekly, and the dose intensity of the two-drug combination is reduced compared with cisplatin/epirubicin. Secondly, there is the suggestion from non-randomised phase II studies that the cumulative response rate to carboplatin in previously untreated patients may be lower than for cisplatin, 31% (27 out of 85 patients) compared with 50% (33 out of 66 patients) (O'Brien et al., 1993) .
Despite these theoretical reservations, this phase II study suggests that infusional ECarboF is as active as ECF and causes less serious toxicity. Comparative response rates for ECarboF vs ECF (Jones et al., 1994) in patients with metastatic breast cancer are 81% vs 83% (complete response rate 17% vs 24%) and with locally advanced disease 81% vs 86% (complete response rate 56% vs 36%). For metastatic disease comparative median response duration data were 8 vs 9 months and median survival was 14 months with both schedules. For locally advanced disease median survival has not yet been reached in either study. Toxicity was reduced with ECarboF compared with ECF, including grade 3/4 emesis (2% vs 28%) and neuropathy (0% vs 2%). It was also of interest that we observed less plantar -palmar erythema (10% vs 26%) and less alopecia requiring a wig (31% vs 56%). Moreover, replacing cisplatin with carboplatin was not associated with a significant increase in severe anaemia (13% vs 5% with ECF) or grade 3-4 leucopenia (19% vs 28%); severe thrombocytopenia, however, occurred in 10% vs 0% (Jones et al., 1994) . Finally ECarboF, as anticipated, could be delivered as outpatient therapy. These comparative data are of course sequential rather than randomised; nevertheless, the criteria for entry were identical, and they suggest that infusional ECarboF has very similar activity to infusional ECF but with less toxicity. Furthermore, cyclophosphamide is a much used drug in breast cancer, with a similar singleagent response rate to carboplatin or cisplatin, and much cheaper. Cyclophosphamide is, therefore, another appropriate candidate to replace cisplatin in the infusional ECF schedule, and we are currently addressing this issue in a randomised phase II trial in patients with metastatic disease.
Both these infusional schedules are highly active against advanced/metastatic breast cancer, with overall response rates higher than those usually reported with conventional chemotherapy regimens (Tormey et al., 1982; Cummings et al., 1985; Falkson et al., 1985; Aisner et al., 1987; Coates et al., 1987; Jodrell et al., 1991; Powles et al., 1991) , albeit in selected patients. Both, however, are also associated with a high relapse rate in patients with metastatic disease, suggesting that their main role may prove to be in the management of patients with high risk early breast cancer (neoadjuvant or adjuvant chemotherapy) or with locally advanced or inflammatory disease. Infusional ECarboF offers a useful step forward compared with ECF in terms of decreased toxicity and the opportunity for outpatient-based chemotherapy. Cost is an obvious but complex factor here: carboplatin is more expensive than cisplatin, but this is balanced by the potential savings of outpatient therapy. These schedules now merit comparison with conventional chemotherapy in randomised trials and we are currently proceeding with two such trials, first as primary/ neoadjuvant chemotherapy for large early breast cancer and second as adjuvant chemotherapy in younger women with involved axillary nodes.
